Back to News
Market Impact: 0.25
Clearmind Advances CMND-100 Into Phase 2a Trial For Alcohol Use Disorder; Stock Down
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsAnalyst InsightsRegulation & Legislation
Clearmind Medicine (CMND) initiated a Phase 2a study in its Phase 1/2a program evaluating CMND-100 for Alcohol Use Disorder (AUD). This is an early clinical development milestone that may support future upside optionality, but provides limited near-term financial impact without efficacy/safety readouts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.10
Ticker Sentiment
CMND0.30
More News
- Indonesia stocks suffer biggest daily slump since 1998 as MSCI weighs downgrade
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- FDA approves Enspryng for thyroid eye disease treatment
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’
- Hybe shares jump 10% as K-pop sensation BTS' tour lifts earnings hopes